Abstract
This viewpoint evaluates California’s CalRx Biosimilar Insulin Initiative, which aims to address insulin affordability by offering less expensive alternatives to existing products, specifically targeting patients with insulin-dependent diabetes.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
